| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.34.1255 |
| P698 | PubMed publication ID | 21990397 |
| P50 | author | Edith A. Perez | Q18389345 |
| Hope Rugo | Q55975497 | ||
| P2093 | author name string | Sara Hurvitz | |
| Vicente Valero | |||
| Adam M Brufsky | |||
| Vincent O'Neill | |||
| Raji Swamy | |||
| P433 | issue | 32 | |
| P921 | main subject | bevacizumab | Q413299 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 4286-4293 | |
| P577 | publication date | 2011-10-11 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | |
| P478 | volume | 29 |
| Q41709095 | A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer |
| Q37048596 | A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. |
| Q38661921 | A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). |
| Q31152878 | An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients |
| Q28079013 | Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer |
| Q38245841 | Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model |
| Q36330281 | Anti-VEGF therapies in the clinic |
| Q33770680 | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions |
| Q26999473 | Anti-vascular endothelial growth factor therapy in breast cancer |
| Q30399006 | Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia |
| Q26822432 | Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials |
| Q26751226 | Antiangiogenic mechanisms and factors in breast cancer treatment |
| Q34989039 | Antiangiogenic therapy for breast cancer |
| Q36563542 | Antiangiogenic therapy for cancer: an update |
| Q47111400 | Antiangiogenic therapy in breast cancer |
| Q90699038 | Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases |
| Q41892380 | Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. |
| Q53834125 | Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. |
| Q37963955 | Benefit-risk assessment of bevacizumab in the treatment of breast cancer. |
| Q36248498 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence |
| Q36298210 | Bevacizumab and breast cancer: what does the future hold? |
| Q33424566 | Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial |
| Q35076351 | Bevacizumab in metastatic breast cancer: when may it be used? |
| Q35696743 | Bevacizumab in the treatment of metastatic breast cancer: friend or foe? |
| Q43497234 | Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups |
| Q38237318 | Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups |
| Q57579457 | Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando |
| Q41612851 | Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis |
| Q36746794 | Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. |
| Q34695003 | Biomarkers for anti-angiogenic therapy in cancer. |
| Q33651388 | Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer |
| Q38852051 | Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment |
| Q35815486 | Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy? |
| Q35599769 | Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. |
| Q43077324 | Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'. |
| Q37672654 | Controlling escape from angiogenesis inhibitors |
| Q55332979 | DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer. |
| Q47405286 | Diffusion of Bevacizumab Across Oncology Practices: An Observational Study |
| Q36999509 | Drug resistance and the role of combination chemotherapy in improving patient outcomes |
| Q35764986 | Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis |
| Q30317067 | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† |
| Q60303037 | Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials |
| Q31060162 | Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature |
| Q26786618 | Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q36209477 | Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials |
| Q90049358 | Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis |
| Q35173951 | Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date |
| Q35075446 | Emerging strategies for treating brain metastases from breast cancer |
| Q54196655 | Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer. |
| Q49662817 | Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer |
| Q26773795 | Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors |
| Q37292020 | Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint |
| Q35870492 | Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance |
| Q34537146 | Factors responsible for long-term survival in metastatic breast cancer |
| Q28078745 | Future paradigms for precision oncology |
| Q35678431 | Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. |
| Q37510240 | Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI. |
| Q93186392 | Immunological Regulation of Vascular Inflammation During Cancer Metastasis |
| Q85902107 | Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy |
| Q87884150 | Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case |
| Q38005357 | Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers |
| Q36729895 | Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials |
| Q54969682 | Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials. |
| Q30248296 | Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials |
| Q36953443 | Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes |
| Q47325013 | Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials. |
| Q86091055 | Length of chemotherapy and use of bevacizumab for breast cancer |
| Q26852509 | Lessons learned from the bevacizumab experience |
| Q35061280 | Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials |
| Q34452673 | Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy |
| Q30249335 | Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. |
| Q38901163 | Metastatic breast cancer: The Odyssey of personalization |
| Q37631514 | Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? |
| Q34544166 | Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer |
| Q34253684 | Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients |
| Q35881780 | Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials |
| Q30542073 | Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers |
| Q36652690 | North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane |
| Q38194452 | Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study |
| Q38004740 | Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia |
| Q37986561 | Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it? |
| Q36526547 | Patterns in target-directed breast cancer research |
| Q28555102 | Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer |
| Q35776220 | Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. |
| Q37234829 | Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) |
| Q50419857 | Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review. |
| Q41134105 | Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel |
| Q37187766 | Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer |
| Q59616684 | Progress against solid tumors in danger: the metastatic breast cancer example |
| Q57109788 | Progress in targeted therapy for breast cancer |
| Q35077775 | Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations |
| Q39311633 | RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer |
| Q45053173 | Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer |
| Q37950515 | Recent developments in treatment stratification for metastatic breast cancer |
| Q64265628 | Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer |
| Q28076777 | Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant |
| Q58729601 | Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials |
| Q33949406 | Risks and benefits with bevacizumab: evidence and clinical implications |
| Q61800397 | Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia |
| Q40384198 | Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival |
| Q34477740 | Soy and breast cancer: focus on angiogenesis |
| Q38046514 | Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer |
| Q33628383 | Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer |
| Q41346534 | Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute |
| Q35687574 | Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. |
| Q36245324 | Targeted therapies in breast cancer: are heart and vessels also being targeted? |
| Q36182795 | Targeting angiogenesis in metastatic breast cancer |
| Q46407140 | Ten years of anti-vascular endothelial growth factor therapy |
| Q34096063 | The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer. |
| Q36865945 | The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most? |
| Q54310257 | The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials. |
| Q37327801 | The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients |
| Q26824086 | The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review |
| Q47134647 | Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies |
| Q36216452 | Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. |
| Q26993238 | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy |
| Q56932681 | Trial watch: Monoclonal antibodies in cancer therapy |
| Q90040642 | Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness |
| Q57140329 | Triple-negative breast cancer |
| Q57115890 | Triple-negative breast cancer and the potential for targeted therapy |
| Q36061177 | Triple-negative breast cancer: are we making headway at least? |
| Q24202199 | Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer |
| Q91997710 | Vessel co-option in cancer |
| Q37407384 | Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases |
| Q30651989 | Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy. |
| Q37236305 | Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. |
| Q35942949 | Window of opportunity: A new insight into sequential bevacizumab and paclitaxel in two cases of metastatic triple-negative breast cancer |
Search more.